Aptose Selling General Administrative from 2010 to 2024

APTO Stock  USD 0.24  0.03  11.11%   
Aptose Biosciences Selling General Administrative yearly trend continues to be very stable with very little volatility. Selling General Administrative is likely to grow to about 16.4 M this year. During the period from 2010 to 2024, Aptose Biosciences Selling General Administrative quarterly data regression pattern had sample variance of 53.8 T and median of  7,046,242. View All Fundamentals
 
Selling General Administrative  
First Reported
1997-06-30
Previous Quarter
2.9 M
Current Value
2.3 M
Quarterly Volatility
M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aptose Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptose Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 83.6 K, Interest Expense of 929.8 K or Selling General Administrative of 16.4 M, as well as many indicators such as Price To Sales Ratio of 12.36, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Aptose financial statements analysis is a perfect complement when working with Aptose Biosciences Valuation or Volatility modules.
  
Check out the analysis of Aptose Biosciences Correlation against competitors.
To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

Latest Aptose Biosciences' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Aptose Biosciences over the last few years. It is Aptose Biosciences' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aptose Biosciences' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Aptose Selling General Administrative Regression Statistics

Arithmetic Mean9,699,919
Geometric Mean6,967,698
Coefficient Of Variation75.65
Mean Deviation5,918,016
Median7,046,242
Standard Deviation7,338,053
Sample Variance53.8T
Range25.3M
R-Value0.83
Mean Square Error17.6T
R-Squared0.70
Significance0.0001
Slope1,369,014
Total Sum of Squares753.9T

Aptose Selling General Administrative History

202416.4 M
202315.6 M
202214.4 M
202119.3 M
202026.3 M
20199.9 M
201810.3 M

About Aptose Biosciences Financial Statements

Aptose Biosciences investors utilize fundamental indicators, such as Selling General Administrative, to predict how Aptose Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Selling General Administrative15.6 M16.4 M

Pair Trading with Aptose Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Aptose Stock

  0.42RNXT RenovoRxPairCorr
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:
Check out the analysis of Aptose Biosciences Correlation against competitors.
To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.92)
Return On Assets
(1.36)
Return On Equity
(6.94)
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.